SCHEMBL10168707

SCHEMBL10168707

COc1nc(N(C)C)cc(Nc2ccccc2)c1C(N)=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 1/20 0.45
OPRD1 P41143 1/20 0.45
SLC2A1 P11166 1/20 0.44
TAAR1 Q96RJ0 1/20 0.43
AKR1C3 P42330 1/20 0.41
AKR1C2 P52895 1/20 0.41
POLB P06746 1/20 0.41
HSD17B10 Q99714 1/20 0.40
MAPT P10636 1/20 0.40
ALOX15 P16050 1/20 0.40
MAPK8 P45983 1/20 0.39
MAPK9 P45984 1/20 0.39
PDE4B Q07343 1/20 0.39
ZAP70 P43403 1/20 0.39
KARS1 Q15046 1/20 0.39
SIRT2 Q8IXJ6 2/20 0.39
SIRT1 Q96EB6 1/20 0.39
SQOR Q9Y6N5 1/20 0.38
CSF1R P07333 2/20 0.38
TGM2 P21980 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10168705 0.84 AKR1C3 (0.42) AKR1C3AKR1C2POLBHSD17B10MAPT
SCHEMBL10168690 0.82 PDE4B (0.52) PDE4BSIRT2SIRT1SQOR
SCHEMBL5765632 0.77 MAPK8 (0.47) POLBMAPTMAPK8MAPK9MEN1
SCHEMBL31361067 0.68 CXCR2 (0.44) TAAR1POLBHSD17B10MAPTALOX15
SCHEMBL10168708 0.68 CXCR2 (0.44) TAAR1POLBHSD17B10MAPTALOX15
SCHEMBL31361069 0.68 CXCR2 (0.44) TAAR1POLBHSD17B10MAPTALOX15
SCHEMBL29442375 0.66 SQOR (0.62) POLBMAPTSQORMEN1KMT2A
SCHEMBL1724047 0.66 KDM4E (0.56) AKR1C3AKR1C2HSD17B10MAPTALOX15
SCHEMBL294128 0.65 AKR1C3 (0.78) AKR1C3AKR1C2PDE4B
SCHEMBL5764704 0.64 POLB (0.45) POLBMAPK8SQORMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8586751-B2 Nicotinamide compounds useful as kinase modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2013-11-19 US disclosed
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MEYERS SQUIBB COMPANY 2012-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS NADK, BTK, NAMPT S1PR1 818/4885OPRD1 4266/4885SLC2A1 2137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.